Gapping down
In reaction to disappointing earnings/guidance: YOD -16.9%, CELP -7%, HNR -5.7%, PLT -2%, .
Select metals/mining stocks trading lower: PAAS -2.5%, GDX -2.1%, ABX -2%, GG -2%, EGO -1.6%, SLV -1.4%, NEM -1.3%, SLW -1.2%, GLD -1.2%, GOLD -1.1%, IAG -1%,
Other news: ADMP -30.8% (receives Complete Response Letter from FDA for its Epinephrine Pre-Filled Syringe NDA), BDSI -25.5% (announces that the primary efficacy endpoint in the Phase 3 clinical study of Clonidine Topical Gel compared to placebo for the treatment of painful diabetic neuropathy did not meet statistical significance), NVGN -6.4% (Novogen and Yale University release data on Cantrixil mode of action), BBEP -6.3% (announces $1 bln strategic investment by EIG Global Energy Partners; lowers common unit distribution), MYL -4.9% (announces the public offering of 35 mln ordinary shares held by subsidiaries of Abbott Laboratories (ABT), representing 31.8% of the shares owned by Abbot), NBG -2.4% (cont uncertainty in Greece)
Analyst comments: OIBR -3.9% (downgraded to Underperform from Sector Perform at RBC Capital Mkts), XLNX -2% (downgraded to Equal-Weight from Overweight at Morgan Stanley), LINE -2% (downgraded to Sell from Neutral at UBS), ALTR -0.5% (downgraded to Underperform from Outperform at Credit Agricole)
In reaction to disappointing earnings/guidance: YOD -16.9%, CELP -7%, HNR -5.7%, PLT -2%, .
Select metals/mining stocks trading lower: PAAS -2.5%, GDX -2.1%, ABX -2%, GG -2%, EGO -1.6%, SLV -1.4%, NEM -1.3%, SLW -1.2%, GLD -1.2%, GOLD -1.1%, IAG -1%,
Other news: ADMP -30.8% (receives Complete Response Letter from FDA for its Epinephrine Pre-Filled Syringe NDA), BDSI -25.5% (announces that the primary efficacy endpoint in the Phase 3 clinical study of Clonidine Topical Gel compared to placebo for the treatment of painful diabetic neuropathy did not meet statistical significance), NVGN -6.4% (Novogen and Yale University release data on Cantrixil mode of action), BBEP -6.3% (announces $1 bln strategic investment by EIG Global Energy Partners; lowers common unit distribution), MYL -4.9% (announces the public offering of 35 mln ordinary shares held by subsidiaries of Abbott Laboratories (ABT), representing 31.8% of the shares owned by Abbot), NBG -2.4% (cont uncertainty in Greece)
Analyst comments: OIBR -3.9% (downgraded to Underperform from Sector Perform at RBC Capital Mkts), XLNX -2% (downgraded to Equal-Weight from Overweight at Morgan Stanley), LINE -2% (downgraded to Sell from Neutral at UBS), ALTR -0.5% (downgraded to Underperform from Outperform at Credit Agricole)